Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


June 02, 2015 4:58 AM ET

Pharmaceuticals

Company Overview of SciClone Pharmaceuticals, Inc.

Executive Profile

Mark Lotter

Former Chief Executive Officer of China Operations and Director, SciClone Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 Board Members in 0 different organizations across 2 different industries.

50--

Background

Mr. Mark Lotter was the Chief Executive Officer of China Operations at SciClone Pharmaceuticals, Inc., from April 2011 to December 14, 2012. Mr. Lotter was the Chief Executive Officer, President, and Director at NovaMed Pharmaceuticals Inc. Prior to founding NovaMed, Mr. Lotter served as Vice President, Commercial Operations of AstraZeneca China. He was largely responsible for turning AstraZeneca to the largest prescription based multinational in China. He served as ...

Corporate Headquarters

950 Tower Lane
Foster City, California 94404

United States

Phone: 650-358-3456
Fax: 650-358-3469

Board Members Memberships

Chief Executive Officer, President, and Director
2011-2012
Former Chief Executive Officer of China Operations and Director

Education

BS
The University of KwaZulu-Natal
MBA
University of South Africa

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Edward M. Kaye M.D., Ph.D.Interim Chief Executive Officer, Chief Medical Officer and Senior Vice President
Sarepta Therapeutics, Inc.
$399.0K
Arthur P. Bedrosian J.D.Chief Executive Officer, Director and Chairman of Strategic Planning Committee
Lannett Company, Inc.
$539.0K
Craig A. Wheeler Chief Executive Officer, President and Executive Director
Momenta Pharmaceuticals Inc.
$643.4K
Douglas L. Drysdale Chairman, Chief Executive Officer and President
Pernix Therapeutics Holdings, Inc.
$814.6K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SciClone Pharmaceuticals, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.